.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Marina Kremyanskaya, MD, PhD

Marina Kremyanskaya, MD, PhD, is an associate professor of medicine in Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York.

Articles

Dr Kremyanskaya on the Mechanism of Action of Divesiran in Polycythemia Vera

July 11th 2025

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Dr Kremyanskaya on the Use of Cytoreductive Measures in PV and ET

December 1st 2023

Marina Kremyanskaya, MD, PhD, discusses disease and patient characteristics that influence the choice between hydroxyurea and interferon therapy for patients with polycythemia vera or essential thrombocythemia.

Dr Kremyanskaya on the Safety of Rusfertide in Phlebotomy-Dependent PV

August 25th 2023

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Kremyanskaya on the Promise of Rusfertide in Phlebotomy-Dependent PV

August 24th 2023

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Kremyanskaya on the Rationale for Investigating Rusfertide in Phlebotomy-Dependent PV

August 3rd 2023

Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.

Dr Kremyanskaya on the Efficacy of Rusfertide in Phlebotomy-Dependent Polycythemia Vera

June 16th 2023

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

Dr. Kremyanskaya on the Next Steps of the MANIFEST Trial in Myelofibrosis

January 3rd 2022

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Kremyanskaya on the Design of the MANIFEST Trial in Myelofibrosis

December 21st 2021

Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.

Dr. Kremyanskaya on MANIFEST Trial With CPI-0610 in Myelofibrosis

March 26th 2020

Marina Kremyanskaya, MD, PhD, discusses the goals of the phase II MANIFEST trial examining the efficacy of CPI-0610 in patients with myelofibrosis.

Dr. Kremyanskaya on Unmet Needs in Myelofibrosis

February 27th 2020

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.